Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 8:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–4 of 4 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Epithelioid Hemangioendothelioma (EHE) Clear all
Active, not recruiting Phase 2 Interventional Results available
View directory record Official record
Conditions
Angiosarcoma, Epithelioid Hemangioendothelioma
Interventions
Eribulin
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced May 21, 2026, 8:09 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Epithelioid Hemangioendothelioma (EHE)
Interventions
nab-Sirolimus
Drug
Lead sponsor
Sarcoma Alliance for Research through Collaboration
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
6
States / cities
Stanford, California • Aurora, Colorado • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced May 21, 2026, 8:09 PM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Solid Tumors, Adult, Solid Tumor, Malignant Pleural Mesothelioma (MPM), Epithelioid Hemangioendothelioma (EHE), NF2 Deficient Mesothelioma, Other NF2 Deficient Solid Tumors and Solid Tumors with YAP1/TAZ Fusion Genes, NF2 Deficiency, YAP1 or TAZ Gene Fusions
Interventions
IK-930, Osimertinib
Drug
Lead sponsor
Ikena Oncology
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
9
States / cities
Chicago, Illinois • Boston, Massachusetts • Grand Rapids, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2024 · Synced May 21, 2026, 8:09 PM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Mesothelioma, Epithelioid Hemangioendothelioma(EHE), Solid Tumor
Interventions
BGC515
Drug
Lead sponsor
BridGene Biosciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 8, 2024 · Synced May 21, 2026, 8:09 PM EDT